Innogenetics Weighs Solvay’s Sweetened Takeover Offer Trumping Gen-Probe
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe says it will not increase its offer for Belgian molecular diagnostics firm Innogenetics now that drug maker Solvay has submitted a higher bid, worth $316 million for all of Innogenetics' outstanding shares